About
Technology
Issues
FAQ
Links
Official Page
Phase I, open-label ascending dose trial of anti–CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti–PD-1/PD-L1 therapy
site/software ©
exaly
; All materials licenced under
CC by-SA
.